The main issue for the company is that Amgen’s rival KRAS inhibitor Lumykras (sotorasib) has already been given conditional approval in the EU, so the CHMP considers that Mirati was unable to ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...